enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Pomalidomide - Wikipedia

    en.wikipedia.org/wiki/Pomalidomide

    Pomalidomide, sold under the brand names Pomalyst and Imnovid, [7] [8] is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma. [ 7 ] Pomalidomide was approved for medical use in the United States in February 2013, [ 10 ] and in the European Union in August 2013. [ 8 ]

  3. Cereblon E3 ligase modulator - Wikipedia

    en.wikipedia.org/wiki/Cereblon_E3_ligase_modulator

    The thalidomide molecule is a synthetic derivative of glutamic acid and consists of a glutarimide ring and a phthaloyl ring (Figure 5). [15] [16] Its IUPAC name is 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione and it has one chiral center [15] After thalidomide's selective inhibition of TNF-α had been reported, a renewed effort was put in thalidomide's clinical development.

  4. Oral Anti-Cancer Therapy Pomalidomide Now Approved by ... - AOL

    www.aol.com/2013/08/09/oral-anti-cancer-therapy...

    Oral Anti-Cancer Therapy Pomalidomide Now Approved by European Commission as Treatment for Patients with Relapsed/Refractory Multiple Myeloma - a Rare Form of Blood Cancer BOUDRY, Switzerland ...

  5. Iberdomide - Wikipedia

    en.wikipedia.org/wiki/Iberdomide

    Iberdomide is an experimental thalidomide analog [1] that works as an cereblon E3 ligase modulator; it has a higher binding affinity than lenalidomide or pomalidomide.

  6. Celgene Corporation Announces Pomalidomide Will Be Reviewed ...

    www.aol.com/2012/09/19/celgene-corporation...

    For premium support please call: 800-290-4726 more ways to reach us

  7. IVIVC - Wikipedia

    en.wikipedia.org/wiki/IVIVC

    An in-vitro in-vivo correlation (IVIVC) has been defined by the U.S. Food and Drug Administration (FDA) as "a predictive mathematical model describing the relationship between an in-vitro property of a dosage form and an in-vivo response".

  8. Melphalan flufenamide - Wikipedia

    en.wikipedia.org/wiki/Melphalan_flufenamide

    In October 2021, Oncopeptides AB announced the withdrawal of Pepaxto from the US market after the OCEAN trial's data showed no improvement in terms of overall survival versus pomalidomide in the ITT group (19.8 months in the melphalan flufenamide group versus 25.0 months in the pomalidomide group, HR 1.10, 95% CI 0.85–1.44, p = 0,47). [24] [25]

  9. Elotuzumab - Wikipedia

    en.wikipedia.org/wiki/Elotuzumab

    Elotuzumab is indicated for adult patients in combination treatment for multiple myeloma in patients that have received 1 to 3 prior therapies. [3] For medical use in multiple myeloma patients, elotuzumab can be combined with either lenalidomide and dexamethasone or pomalidomide and dexamethasone. [3]